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Although normally commensals in humans, Candida albicans, Candida tropicalis, Candida parapsilosis, Candida glabrata, and
Candida krusei are capable of causing opportunistic infections in individuals with altered physiological and/or immunological
responses. These fungal species are linked with a variety of infections, including oral, vaginal, gastrointestinal, and systemic
infections, with C. albicans the major cause of infection. To assess the ability of diﬀerent Candida species and strains to cause
infection and disease requires the use of experimental infection models. This paper discusses the mucosal and systemic models
of infection available to assay Candida virulence and gives examples of some of the knowledge that has been gained to date from
these models.
1.Candida and Man
1.1. Carriage of Candida Species. In healthy individuals Can-
dida species are harmless members of the normal gastroin-
testinal (GI), oral, and vaginal microbial ﬂora. It is assumed
that everyone carries Candida in their GI tract (reviewed in
[1]), with C. albicans the species most frequently identiﬁed
in faecal sampling, representing 40–70% of isolates [2–4].
Other isolates are usually identiﬁed as C. parapsilosis, C. gla-
brata, C. tropicalis, or C. krusei [2–4].
In comparison to GI carriage, oral carriage is observed in
only ∼40% of healthy individuals, with considerable varia-
tionfoundbetweenstudies(reviewedin[1]).Highercarriage
levels are generally associated with diabetes, cancer, HIV, or
denture use (reviewed in [1]). Again, the majority of isolates
(∼80%) are identiﬁed as C. albicans,w i t hC. glabrata or C.
parapsilosis making up the remainder [5–9].
Vaginal carriage occurs in an even smaller proportion of
the healthy population, with only ∼20% of healthy women
foundtohavevaginalCandida carriage[10–13].C.albicans is
again the most commonly identiﬁed species, with C. glabrata
the only other species usually found [10, 12, 14–17].
Therefore, C. albicans is the major species found as a
commensal in healthy individuals, with four other species,
C. tropicalis, C. parapsilosis, C. glabrata, and C. krusei,a l s o
found.
1.2. Candidaand Disease. Candida species, however, havean
alternative lifestyle, causing opportunistic infection in hosts
with altered physiological or immune response. The infec-
tions caused by Candida species range from self-limiting,
superﬁcialmucosallesions(commonlyreferredtoasthrush),
chronic and/or recurrent mucosal, skin, and nail infections,
through to life-threatening invasive or disseminated infec-
tion [1, 18–21].
In humans, the most common infections caused by Can-
dida species are superﬁcial infections of the mucosa, skin,
and nails [20–24]. Pseudomembranous oral thrush is com-
mon in babies and in the elderly, but is also found in HIV-
positiveindividualsandcancerpatients(reviewedin[1,25]).
Denture stomatitis is also a signiﬁcant infection, occurring
in approximately 60% of denture wearers [26, 27]. In oral
candidiasis most infections are caused by C. albicans (58%),2 International Journal of Microbiology
with the remainder caused by C. parapsilosis, C. tropicalis, C.
glabrata, and C. krusei [28, 29].
Vaginal candidiasis, or thrush, another form of superﬁ-
cial infection, aﬀects approximately 75% of women of child-
bearing age [30, 31]. C. albicans is most commonly isolated,
with C. glabrata also found, but at a lower frequency [17, 30,
32–35], reﬂecting the species normally carried in the vulvo-
vaginal area.
An additional form of candidiasis involving the mucous
membranes, as well as the skin and nails, is chronic muco-
cutaneous candidiasis. Unlike other forms of candidiasis,
there is evidence that this condition can be inherited or is
associatedwiththymoma,withalmosteveryinfectioncaused
by C. albicans [20–24, 36].
The most serious infections caused by Candida species,
however, are invasive or disseminated infections. Candida
species cause ∼11% of all bloodstream infections and 20%
of those occurring in the ICU population [37–39]. However,
in comparison to bacterial infections occurring in the same
patient population, these infections are much more serious
as mortality rates remain high (∼45%) [1, 40]. This is
due, in part, to diagnostic diﬃculties and limited antifungal
therapies. Invasive infections occur in those patients who are
already seriously ill, with major risk factors including admis-
sion to ICU, surgery (especially abdominal surgery), and
neutropenia(reviewedin[1]).TheﬁveCandida speciescom-
monly isolated from the human GI tract are also responsible
for 90% of invasive Candida infections [1, 41]. Geographical
variations in the epidemiology of these infections do occur,
with C. tropicalis the most common cause of invasive
Candida infection in both India and Singapore [42–44]. In
addition, in patients with haematological malignancies and
in young children and babies, there is increased incidence of
C. tropicalis and C. parapsilosis [45–49].
Patients with invasive Candida infection usually present
with clinical symptoms similar to those associated with
invasive bacterial infection and can eventually developsepsis
[50]. From autopsy reports, it is evident that the lungs and
the kidneys are the organs most commonly aﬀected, with
fungal lesions also found in the heart, liver, and spleen [51–
55]. Infection most likely originates from the GI tract, as
the majority of invasive infections show GI involvement
(oesophagus, stomach, and intestines) [51, 53]a n dCandida
isolatesfromthebloodstream areidentical,orcloselyrelated,
to isolates from nonsterile sites of the same patient [56].
Increasing numbers of patients suﬀering immunosup-
pression and undergoing invasive treatments, for example,
for cancers and organ transplants, mean that thereis an ever-
increasing population at risk of invasive fungal infection.
With a medical need for the development of new and more
eﬃcient diagnostics and therapies for fungal infection, we
need a better understanding of Candida pathogenesis, that
is, how do the major Candida species cause opportunistic
infections?
2.ExperimentalModelsofCandida Infection
Experimental infection models allow disease developmentto
befollowedfromthemomentthatfungalcellsareintroduced
into the host. To be a good model, a model should be re-
producible, relatively easy to set up, and should reproduce
the major clinical symptoms seen in the human disease. It
is also an added advantage if the model is cost eﬀective.
Models which satisfy these conditions allow further in-depth
investigation of Candida virulence to be carried out and,
subsequently, allow inferences about Candida virulence in
human disease to be made.
Although a great deal of preliminary research on viru-
lence can be carried out by laboratory experiment, infection
modelling requires the involvement of a host organism. It
is only in a whole organism that the complex host-fungus
interactions that determine whether or not disease will occur
can be investigated. Although larger animals have been used
to study Candida infections, for example, macaques [57, 58],
piglets [59], rabbits [60–62], and guinea pigs [63, 64], the
majority of Candida virulence studies use rodent infection
models. This is due to economic factors, ease of handling,
and the availability of genetically modiﬁed mouse strains,
which allow human genetic conditions to be mimicked.
In this paper, experimental animal models that have
been developed for Candida virulence assays are discussed.
It should be noted that the majority of models focus on C.
albicans as this is the major species associated with human
Candida infections.
2.1. Mucosal Infection Models. To model Candida oral and
vaginal infections, mucosal models have been developed
mainly in rats and mice. The procedures used in rats and
mice are generally similar. However, the larger animal has
the added advantage that denture-associated fungal bioﬁlms
formationcanalsobestudiedinahost[65].Establishmentof
infection at mucosal sites generally requires treatment with
immunosuppressive agents,oestrogen, orantibioticspriorto
infection, or the use of germ-free animals [66–68]. However,
the nude (Foxn1nu) mouse model of oral infection allows in-
fection to be established without any immunosuppression or
other pretreatment [69]. Greater detail canbe found in more
extensive reviews of these infection models [67, 68, 70, 71].
In order to assess virulence in mice using the oral
infection model, mice are routinely pretreated with corti-
costeroids and Candida cells are administered into the oral
cavityof anaesthetised animals either byapplyinga Candida-
soaked cotton bud under the tongue or by applying the
inoculum directly onto the teeth, gums, and oral cavity
[67, 70, 72]. Virulence in this model is usually determined
by fungal organ burden and histopathology.
Both rat and mouse models have been used to compare
the virulence of C. albicans mutant strains and also clinical
isolates [73–77]. Using these models, C. albicans mutant
strains which are unable to switch between the yeast and hy-
phal growth forms were found to be unable to cause oral
infection, demonstrating a requirement for yeast-hypha
switching in oral infection [75]. In addition, protein kinase
Ck2 was also shown to be required for oropharyngeal C.
albicans infections [77].
Mouse and rat models have also been developed to assay
Candida virulence in vaginal infection. In these models the
rodents are maintained in oestrus in order to maintainInternational Journal of Microbiology 3
colonisation and infection, which probably mimics preg-
nancy-associated candidiasis [78–81]. In rats, this generally
involves surgery to remove the ovaries, with subsequent
administration of oestrogen [81]. Recently, however, a new
rat model has been developed, similar to the mouse model,
where oestrus is maintained merely through administration
of oestrogen [82], which will increase the ease of setting
up the infection model. Immunosuppression of the host
can also prolong colonisation by Candida species [83].
These models allow us to examine single vaginitis episodes;
however, a satisfactory model of recurrent, chronic vaginitis
is not yet available.
The virulence of C. albicans clinical isolates has been
compared in rodent vaginitis models, demonstrating that
isolates havevarying capacitiesto cause disease [84, 85]. This
model has also been used to assess virulence of genetically
modiﬁed C. albicans mutants [85–87].
In addition to assessing C. albicans virulence, this model
can be used to examine virulence of other Candida species.
As C. glabrata is also associated with human vaginal infec-
tion,researchers haveused theratvaginitis modeltoevaluate
the virulence of a C. glabrata petite mutant, discovering than
the mutant was more virulent that the parental strain [88].
In addition, C. parapsilosis isolates have also been assessed
for their ability to cause vaginal infection in the rat model
[80] .I nt h i ss t u d yo n l yas i n g l ei s o l a t e ,r e c e n t l yo b t a i n e d
from a woman with active vaginal infection, was capable of
initiating infection [80].
A major development in Candida virulence testing at
mucosal surfaces occurred recently with the development of
a concurrent oral and vaginal infection model by Rahman
et al. [72]. This mouse model allows both oral and vaginal
infections to be initiated in the same host, greatly reducing
the numbers of animals required for these virulence assays.
A comparison of the virulence of three diﬀerent C. albicans
isolates in this model clearly demonstrated that C. albicans
isolates were not equallyvirulent, with obvious diﬀerencesin
their ability to initiate mucosal infections [72].
2.2. Invasive Infection Models. Mouse models of invasive
fungal infection have been the most popular methods to
assess Candida virulence up until the present day, although
assays have also been carried out in rabbits, guinea pigs,
and rats also used in some studies. There are two major
models of Candida invasive infection, the intravenous (IV)
challenge model and the gastrointestinal (GI) colonisation
with subsequent dissemination model. These models were
recently reviewed [89].
2.2.1. Intravenous Challenge Model. The mouse IV challenge
model has been used to study Candida virulence since the
1960s and is both well characterised and reproducible [90–
92]. Candida cells are injected directly into the lateral tail
vein, bypassing any requirement of the fungus to cross
epithelial and endothelial barriers to gain entry into the
bloodstream. In this mouse model, which is similar to hu-
man invasive infection occurring with catheter involvement,
fungal cells are found in all organs, but disease progresses
only in the kidneys and brain, which depends upon inocu-
lum level and mouse strain [91–93]. Sepsis develops as
invasive disease progresses, which eventually leads to the
death of the mouse [92, 94, 95].
In these models of Candida invasive infection, virulence
isdeterminedbymonitoringsurvival ofinfectedmiceand/or
by quantifying fungal organ burdens at predetermined times
after infection. Drug treatments can also be administered
to the host to allow host conditions to be mimicked, for
example, immunosuppression [88, 96–110]o rd i a b e t e s[ 99],
with greater Candida virulence in both of these treatments.
Using immunocompetent mice, the IV challenge model
has been used to compare the virulence of diﬀerent Candida
species [97–99, 107, 111–114]. C. albicans is clearly the most
virulentspecies[97, 98, 111, 112, 114],followed closely by C.
tropicalis [97, 98, 111, 112, 114]. In contrast, C. krusei and C.
parapsilosis were unable to kill the infected animals, even at
high inoculumlevels,and fungi were eventuallycleared from
the host [98, 111, 114].
In immunosuppressed mice, C. tropicalis showed greater
virulence, with disease progressing in the kidneys, rather
than infection being controlled which occurs in immuno-
competent mice [96, 98, 99, 107, 115]. C. parapsilosis and
C. krusei remained unable to initiate progressive infections,
even with addition of immunosuppressive treatments [98,
107], although administration of a very high inoculum
potentially allows some C. parapsilosis isolates to initiate
disease [108, 110].
Within each Candida species, clinical isolates were found
toshowconsiderablevirulencediﬀerencesintheIVchallenge
model. This was true for C. albicans [97, 107, 116, 117], C.
tropicalis [97, 99, 112, 115, 118], and C. parapsilosis [108,
119],with someisolates unabletoinitiate invasive infections.
This raises questions as to whether virulence results found
for a single strain or isolate are representative of the entire
species.ThiscouldbeofparticularimportanceforC.albicans
studies where the vast majority of gene disruption studies
havebeencarried outinasingle strain, SC5314,background.
Numerous studies have evaluated C. tropicalis clinical
isolate virulence diﬀerences; however, there are very few
studies published on the virulence of genetically modiﬁed
C. tropicalis strains. One study which has been published
was able to demonstrate that a secreted acid protease was
required for full virulence of C. tropicalis in immunocom-
petent mice [120]. In contrast to C. tropicalis,v a s tn u m b e r s
ofstudieshave beenpublished onthe virulenceof C. albicans
mutants,withover200genesidentiﬁedascontributingtothe
C. albicans virulence in this model (reviewed in [89]).
C. glabrata behaves very diﬀerently from the other Can-
dida species in the mouse model of invasive infection. Al-
though C. glabrata is maintained, or tolerated, at high levels
in the kidneys of immunocompetent mice, the mice did
not die and there was little inﬂammation associated with
the fungal cells [113, 114]. Immunosuppression appears to
increase virulence of C. glabrata in terms of higher fungal
organ burdens, but mouse survival is only increased in some
C. glabrata infections [100, 103–106]. However, because
immunosuppression may allow invasivedisease todevelopin
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to an infection model used in some studies to compare the
virulence of genetically modiﬁed C. glabrata,w i t hf u n g a l
burdens used as the virulence estimate [88, 101, 102, 105].
The immunosuppressed mouse infection model has demon-
strated the importance of hypertonic stress responses, the
cell wall integrity pathway, and nitrogen starvation responses
in C. glabrata virulence [103, 104, 106]. In addition, this
model has identiﬁed a petite mutant, strains expressing
hyperactive alleles of the transcription factor gene PDR1 and
theace2 null mutantas beingmore virulentthan their parent
strains [88, 105, 121]. However, it should be noted that the
hypervirulent phenotype of the C. glabrata ace2 null was
completely lost in immunocompetent mice [122]. In other
virulence experiments in immunocompetent mice, where
virulence was determined from fungal organ burdens at day
7 after infection, researchers were able to demonstrate that
t h ec e l lw a l li n t e g r i t yp a t h w a y[ 123, 124]a n do x i d a t i v es t r e s s
response [125], as well as the transcription factor Pdr1p and
some of the genes that it regulates [101, 121], contribute to
C. glabrata virulence.
2.2.2. Gastrointestinal Colonisation and Dissemination Model.
Gastrointestinal models can either be set up in neonatal
or adult mice. Intragastric infection of neonatal mice leads
to persistent colonisation, without any requirement for
pretreatment of the mice. However, to obtain colonisation of
adultmice,thenaturalmousegastrointestinal ﬂoramustﬁrst
be removed by treatment with broad spectrum antibiotics.
Adult mice can either be infected by gavage (intragastrically)
or orally via their chow or drinking water. Subsequent
treatment of Candida colonised mice with immunosuppres-
sants and/or drugs which damage the gut wall allow fungal
dissemination to occur (reviewed in [70, 126]).
In the gastrointestinal models fungal colonisation is
highest in the stomach, caecum, and small intestine [107,
127–129], reﬂecting some of the clinical ﬁndings seen in hu-
man invasive infection. During the model, persistent coloni-
sation is routinely monitored by noninvasive faecal fungal
counts,andafterdissemination Candida cellscanbecultured
from the liver, kidneys, and spleen [128–130]. However, dif-
ferences may be seen between mouse strains [131].
This murine model is believed to be a more accurate re-
ﬂection of the events occurring in the human patient, with
broad spectrum antibiotics allowing fungal overgrowth and
later invasive therapies causing mucosal damage. Mucosal
damage then allows Candida to enter the bloodstream and
disseminate to the internal organs. In the mouse, similar to
human patients, there is increased animal-to-animal varia-
tioncompared tothe intravenous challenge model,requiring
higher numbers of animals per group to obtain statistically
signiﬁcant results [128–130].
Comparison of Candida species virulence in this model
demonstrated that C. parapsilosis had lower virulence com-
pared to C. albicans and C. tropicalis, as there was little
evidence of dissemination from the gut [107, 132]. How-
ever, C. parapsilosis was successful in establishing persistent
colonisation of the GI tract [107]. In separate studies, C.
tropicalis appeared to be more virulent than C. albicans in
the gastrointestinal model, with greater dissemination to
the internal organs [133, 134] and higher mortality rates
[97, 134]. However, given the levels of variation observed in
other models forthe virulence ofstrains of diﬀerentCandida
species, further isolates will require to be assayed before a
deﬁnitive conclusion on the relative virulence of the two
species can be made.
To date, only a limited number of C. albicans mutant
strains have been tested in the gastrointestinal colonisation
and dissemination infection model, with only 6 mutants
identiﬁed so far as contributing to virulence [89, 135]. How-
ever, this model has demonstrated that a constitutively ﬁla-
mentous C. albicans mutant was unable to disseminate, sug-
gesting that the ability to switch between morphological
forms may be more important for dissemination [136].
C. glabrata also behaved diﬀerently from the other four
major Candida species in this model, being unable to colo-
nise the oesophageal tissue in the neonatal mouse gastroin-
testinal colonisation and dissemination model [137]. Again,
there was little host inﬂammatory response to C. glabrata
[137], suggesting that C. glabrata virulence mechanisms may
be quite diﬀerent from those of the other species studied.
3.Beyond the Genome:ChallengesofCandida
VirulenceTesting inthe PostgenomicEra
The genome sequences of C. albicans, C. glabrata, C. tropi-
calis, andC.parapsilosis are nowavailable[138,139],encour-
aging the creation of large-scale mutant libraries. The chal-
lenge comes, however, when these large libraries are to be
screened for genes involved in fungal virulence, with logis-
tical, ﬁnancial, and ethical issues to be considered.
In library screening programmes carried out to date
diﬀerent virulence testing strategies have been taken. Noble
et al. [140] used signature-tagged mutagenesis to allow pools
of mutants to be assayed in small numbers of animals, sig-
niﬁcantly reducing the animal numbers required for testing.
By contrast, in order to screen a library of 177 C. albicans
strains for altered virulence, Becker et al. [141] assayed each
strain in 15 mice. From these two examples it is clear that
traditional testing methods can lead to large numbers of
mice being required to assay virulence. However, researchers
have recently begun to address the issues of virulence testing
large numbers of Candida strains by developing a range of
minihosts, which are mainly based on invertebrate hosts.
Minihosts may notinitially appear relevant tothehuman
disease, but these hosts do possess an innate immune system
and this is known to be critical in the development of
Candida infections [142]. However, many of the minihosts
do not possess an adaptive immune system, which may limit
their usefulness. In addition, the majority of invertebrate
models have the disadvantage that they must be kept at
temperatures below normal human body temperature, with
the exception of Galleria which can be incubated at 37◦C.
Potentially, incubation at lower temperatures may induce
physiological changes in the fungus, aﬀecting host-fungus
interactions during disease development.
3.1. Wax Moth and Silk Worm Larval Models. The ﬁrst
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theGalleria mellonella (waxmoth)larvalmodel[143].Inthis
modelfungiareinjectedintolarvae,viaaproleg,andsurvival
ismonitored overashort timeperiod. Themodel isrelatively
cheap and has the added advantage that large numbers of
larvae canbeinfected with each mutantstrain, increasing the
statistical power of the assay. The Galleria model has been
successfully used to model C. albicans virulence, with results
roughly similar to those found in mouse infection models
[143–146]. A similar model has also been developed using
the silk worm (Bombyx mori)[ 147, 148]. Both C. albicans
andC.tropicalis are capableofkillingsilkwormlarvaewithin
two days [148], and C. albicans virulence diﬀerences were
shown to correlate with results previously found in a mouse
model [147].
3.2. Drosophila melanogaster. The fruit ﬂy, Drosophila mela-
nogaster, hasalso beenused to assay Candida virulence[149–
152]. The susceptibility of wild-type D. melanogaster contin-
ues to be debated; however, both Toll- and Sp¨ atzle-deﬁcient
fruit ﬂies are susceptible to infection by Candida species
when fungi are injected directly into the thorax [149–151].
Again, D. melanogaster models also have the advantage that
large numbers of ﬂies (>30 ﬂies) can be infected with each
Candida strain, increasing the statistical power of the assay.
In fruit ﬂies, C. albicans was shown to be more virulent
than other Candida species, conﬁrming the results found in
mammalian models(seeabove;[149]).Inaddition,virulence
results for C. albicans clinical isolates and mutants were
broadly similar to those found in the mouse systemic model
[149–151]. However, diﬀerences do occur. In the fruit ﬂy,
CO2 sensing is important for virulence, but this was not the
case in the mouse IV challenge model [153]. This model has
already been successfully used to screen a C. albicans mutant
library, identifying Cas5, a transcription factor involved in
cell wall integrity, as being required for full virulence [154].
In addition to the systemic D. melanogaster infection
model, a new gastrointestinal infection model has also been
developed recently, which should provide new options for
virulence screening in a gastrointestinal model [152].
3.3. Caenorhabditis elegans. In addition to ﬂy and larval
models, the nematode Caenorhabditis elegans has also been
evaluated as an infection model for assaying Candida vir-
ulence [155]. This model is particularly suited to high-
throughput screening, as the Candida cells are fed to the
nematodes in their food and assays are carried out in multi-
well plates. This model has also been used successfully to
screen a C. albicans transcription factor mutant library,
allowing identiﬁcation of transcription factor genes involved
in hypha formation [155].
3.4. A Vertebrate Minihost: Zebraﬁsh (Danio rerio). Zebraﬁsh
are the ﬁrst vertebrate minihost model developed for vir-
ulence testing of Candida. This organism has the added
advantage of having both innate and adaptive immune
systems [156], and methods are also available to allow ﬁsh
gene expression to be manipulated to mimic human genetic
conditions [157].
The ﬁrst virulence assay developed in zebraﬁsh involved
intraperitoneal injection of C. albicans into 7-month-old
zebraﬁsh [158]. In this model, similar to mouse models,
progressive infection depends upon dose and is associ-
ated with increased proinﬂammatory gene expression. This
model also allows increased group sizes, with group sizes
of 20 ﬁsh being used to date. Using this model, researchers
demonstrated that a clinical isolate with reduced virulencein
a mouse model also showed reduced virulence in this model
[158]. In addition, a C. albicans mutant (efg1/cph1)k n o w n
to have attenuated virulence due to ﬁlamentation defects
also had reduced virulence in this model [159, 160]. Of
greater interest was the ﬁnding that, although these mutants
were unable to form ﬁlaments in vitro, they clearly formed
ﬁlaments when growing within ﬁsh. This model also allows
interactions between zebraﬁsh immune cells and Candida
cells to be imaged, which will be made even easier in the
future with the development of the new transparent adult
(casper)z e b r a ﬁ s h[ 161].
A second zebraﬁsh infection model has also been de-
scribed, where each ﬁsh larva (36h after fertilization) is in-
fected directly into the hindbrain ventricle with approxi-
mately 10 fungal cells [162]. In this model the C. albicans
efg1/cph1 mutant again demonstrated attenuated virulence,
similar to results found in the mouse IV challenge model
[162].
There are, however, disadvantages to the zebraﬁsh infec-
tion models. One of the major drawbacks of this model, in
commonwith themajority ofotherminihosts, isthattheﬁsh
need to be kept at 28-29◦C, which does not allow accurate
mimicking of human infection.
4.Assaying VirulenceinExperimental
Models: FinalConsiderations
There are some important points to remember when eval-
uating Candida virulence in experimental infections. The
ﬁrst concerns the Candida species of interest. Although
C. albicans, C. tropicalis, C. glabrata, and C. krusei are all
associated with human carriage and infection, they are not
natural mouse commensals or pathogens [163]. As such,
there may be diﬀerent interactions occurring between the
fungusandthetwodiﬀerenthostspecies.Thisisofparticular
relevance when considering C. glabrata and its inability to
initiate disseminated infection in the IV challenge models,
especially when we know that C. glabrata can cause lethal
infections in severely ill humans [164].
The second point to consider is that, although the im-
mune systems of mice and men are similar, there are dif-
ferences that could aﬀect how the host and fungus interact
[165–168]. Of particular relevance to Candida infections are
diﬀerences in proportions of neutrophils and lymphocytes
in the blood, complement receptor expression, and T-cell
diﬀerentiation, to name but a few (reviewed in [168]). In
addition, diﬀerent mouse strains show diﬀering susceptibil-
itytoinfection,which couldpotentiallyaltervirulenceresults
[93, 169–172].
The third point to consider is which model should be
used to evaluate Candida virulence.SomeC. albicans isolates6 International Journal of Microbiology
exhibit virulence diﬀerences depending upon the infection
model being used [72, 134, 173]. A good example is the C.
albicans genome sequenced strain SC5314. In the IV chal-
lenge model, SC5314 is one of the most virulent C. albicans
isolates, causing lethal infection in a relatively short time
[92, 116]; however, in a vaginal infection model, SC5314 is a
very poor coloniser of the vaginal mucosa [72]. In addition,
an o n g e r m i n a t i v eC. albicans strain [173]a n daura3 minus
C. albicans strain [174], both of which were attenuated
in systemic infection models [173, 175–177], successfully
established mucosal infections [173, 174].
Only careful consideration of the above points will allow
the Candida researcher to select the appropriate experimen-
tal Candida infection model to answer a particular research
question. These models remain essential for increasing our
understanding of fungal pathogenesis since both fungal
attributes and host responses are known to contribute to the
development of clinical disease.
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